 | • レポートコード：MRC2012B0372 • 出版社/出版日：GlobalInfoResearch / 2020年12月21日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、103ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、脆弱X症候群の世界市場を広く調査・分析し、今後の市場展望をまとめております。脆弱X症候群の種類別市場規模（ACT-01、AMO-01、ANAVEX-273、AUT-00206、ブリオスタチン-1、カンナビジオール、その他）、用途別市場規模（クリニック、病院、研究センター）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：Aelis Farma SAS、MI.TO. Technology S.r.L.、Confluence Pharmaceuticals LLC、Alcobra Ltd、Marinus Pharmaceuticals, Inc.、AMO Pharma Limited、Ovid Therapeutics Inc.、F. Hoffmann-La Roche Ltd.、Eli Lilly and Company、Neuren Pharmaceuticals Limited、Sage Therapeutics, Inc.、Zynerba Pharmaceuticals, Inc.、 ・地域別グローバル市場分析 2015年-2020年 ・脆弱X症候群の北米市場（アメリカ、カナダ、メキシコ） ・脆弱X症候群のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・脆弱X症候群のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・脆弱X症候群の南米市場（ブラジル、アルゼンチン） ・脆弱X症候群の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：ACT-01、AMO-01、ANAVEX-273、AUT-00206、ブリオスタチン-1、カンナビジオール、その他 ・用途別分析：クリニック、病院、研究センター ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The global Fragile X Syndrome market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Fragile X Syndrome market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Fragile X Syndrome market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Fragile X Syndrome market has been segmented into:
ACT-01
AMO-01
ANAVEX-273
AUT-00206
Bryostatin-1
Cannabidiol
Others
By Application, Fragile X Syndrome has been segmented into:
Clinic
Hopital
Research Center
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Fragile X Syndrome market presented in the report. This section sheds light on the sales growth of different regional and country-level Fragile X Syndrome markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Fragile X Syndrome market.
The report offers in-depth assessment of the growth and other aspects of the Fragile X Syndrome market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Fragile X Syndrome Market Share Analysis
Fragile X Syndrome competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Fragile X Syndrome sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Fragile X Syndrome sales, revenue and market share for each player covered in this report.
The major players covered in Fragile X Syndrome are:
Aelis Farma SAS
MI.TO. Technology S.r.L.
Confluence Pharmaceuticals LLC
Alcobra Ltd
Marinus Pharmaceuticals, Inc.
AMO Pharma Limited
Ovid Therapeutics Inc.
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Neuren Pharmaceuticals Limited
Sage Therapeutics, Inc.
Zynerba Pharmaceuticals, Inc.
Table of Contents
1 Fragile X Syndrome Market Overview
1.1 Product Overview and Scope of Fragile X Syndrome
1.2 Classification of Fragile X Syndrome by Type
1.2.1 Global Fragile X Syndrome Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Fragile X Syndrome Revenue Market Share by Type in 2019
1.2.3 ACT-01
1.2.4 AMO-01
1.2.5 ANAVEX-273
1.2.6 AUT-00206
1.2.7 Bryostatin-1
1.2.8 Cannabidiol
1.2.9 Others
1.3 Global Fragile X Syndrome Market by Application
1.3.1 Overview: Global Fragile X Syndrome Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Clinic
1.3.3 Hopital
1.3.4 Research Center
1.4 Global Fragile X Syndrome Market by Regions
1.4.1 Global Fragile X Syndrome Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Fragile X Syndrome (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Fragile X Syndrome Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Fragile X Syndrome Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Fragile X Syndrome Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Fragile X Syndrome Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Fragile X Syndrome Status and Prospect (2015-2025)
2 Company Profiles
2.1 Aelis Farma SAS
2.1.1 Aelis Farma SAS Details
2.1.2 Aelis Farma SAS Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Aelis Farma SAS SWOT Analysis
2.1.4 Aelis Farma SAS Product and Services
2.1.5 Aelis Farma SAS Fragile X Syndrome Revenue, Gross Margin and Market Share (2018-2019)
2.2 MI.TO. Technology S.r.L.
2.2.1 MI.TO. Technology S.r.L. Details
2.2.2 MI.TO. Technology S.r.L. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 MI.TO. Technology S.r.L. SWOT Analysis
2.2.4 MI.TO. Technology S.r.L. Product and Services
2.2.5 MI.TO. Technology S.r.L. Fragile X Syndrome Revenue, Gross Margin and Market Share (2018-2019)
2.3 Confluence Pharmaceuticals LLC
2.3.1 Confluence Pharmaceuticals LLC Details
2.3.2 Confluence Pharmaceuticals LLC Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Confluence Pharmaceuticals LLC SWOT Analysis
2.3.4 Confluence Pharmaceuticals LLC Product and Services
2.3.5 Confluence Pharmaceuticals LLC Fragile X Syndrome Revenue, Gross Margin and Market Share (2018-2019)
2.4 Alcobra Ltd
2.4.1 Alcobra Ltd Details
2.4.2 Alcobra Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Alcobra Ltd SWOT Analysis
2.4.4 Alcobra Ltd Product and Services
2.4.5 Alcobra Ltd Fragile X Syndrome Revenue, Gross Margin and Market Share (2018-2019)
2.5 Marinus Pharmaceuticals, Inc.
2.5.1 Marinus Pharmaceuticals, Inc. Details
2.5.2 Marinus Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Marinus Pharmaceuticals, Inc. SWOT Analysis
2.5.4 Marinus Pharmaceuticals, Inc. Product and Services
2.5.5 Marinus Pharmaceuticals, Inc. Fragile X Syndrome Revenue, Gross Margin and Market Share (2018-2019)
2.6 AMO Pharma Limited
2.6.1 AMO Pharma Limited Details
2.6.2 AMO Pharma Limited Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 AMO Pharma Limited SWOT Analysis
2.6.4 AMO Pharma Limited Product and Services
2.6.5 AMO Pharma Limited Fragile X Syndrome Revenue, Gross Margin and Market Share (2018-2019)
2.7 Ovid Therapeutics Inc.
2.7.1 Ovid Therapeutics Inc. Details
2.7.2 Ovid Therapeutics Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Ovid Therapeutics Inc. SWOT Analysis
2.7.4 Ovid Therapeutics Inc. Product and Services
2.7.5 Ovid Therapeutics Inc. Fragile X Syndrome Revenue, Gross Margin and Market Share (2018-2019)
2.8 F. Hoffmann-La Roche Ltd.
2.8.1 F. Hoffmann-La Roche Ltd. Details
2.8.2 F. Hoffmann-La Roche Ltd. Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 F. Hoffmann-La Roche Ltd. SWOT Analysis
2.8.4 F. Hoffmann-La Roche Ltd. Product and Services
2.8.5 F. Hoffmann-La Roche Ltd. Fragile X Syndrome Revenue, Gross Margin and Market Share (2018-2019)
2.9 Eli Lilly and Company
2.9.1 Eli Lilly and Company Details
2.9.2 Eli Lilly and Company Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Eli Lilly and Company SWOT Analysis
2.9.4 Eli Lilly and Company Product and Services
2.9.5 Eli Lilly and Company Fragile X Syndrome Revenue, Gross Margin and Market Share (2018-2019)
2.10 Neuren Pharmaceuticals Limited
2.10.1 Neuren Pharmaceuticals Limited Details
2.10.2 Neuren Pharmaceuticals Limited Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Neuren Pharmaceuticals Limited SWOT Analysis
2.10.4 Neuren Pharmaceuticals Limited Product and Services
2.10.5 Neuren Pharmaceuticals Limited Fragile X Syndrome Revenue, Gross Margin and Market Share (2018-2019)
2.11 Sage Therapeutics, Inc.
2.11.1 Sage Therapeutics, Inc. Details
2.11.2 Sage Therapeutics, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Sage Therapeutics, Inc. SWOT Analysis
2.11.4 Sage Therapeutics, Inc. Product and Services
2.11.5 Sage Therapeutics, Inc. Fragile X Syndrome Revenue, Gross Margin and Market Share (2018-2019)
2.12 Zynerba Pharmaceuticals, Inc.
2.12.1 Zynerba Pharmaceuticals, Inc. Details
2.12.2 Zynerba Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Zynerba Pharmaceuticals, Inc. SWOT Analysis
2.12.4 Zynerba Pharmaceuticals, Inc. Product and Services
2.12.5 Zynerba Pharmaceuticals, Inc. Fragile X Syndrome Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Fragile X Syndrome Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Fragile X Syndrome Players Market Share
3.2.2 Top 10 Fragile X Syndrome Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Fragile X Syndrome Revenue and Market Share by Regions
4.2 North America Fragile X Syndrome Revenue and Growth Rate (2015-2020)
4.3 Europe Fragile X Syndrome Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Fragile X Syndrome Revenue and Growth Rate (2015-2020)
4.5 South America Fragile X Syndrome Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Fragile X Syndrome Revenue and Growth Rate (2015-2020)
5 North America Fragile X Syndrome Revenue by Countries
5.1 North America Fragile X Syndrome Revenue by Countries (2015-2020)
5.2 USA Fragile X Syndrome Revenue and Growth Rate (2015-2020)
5.3 Canada Fragile X Syndrome Revenue and Growth Rate (2015-2020)
5.4 Mexico Fragile X Syndrome Revenue and Growth Rate (2015-2020)
6 Europe Fragile X Syndrome Revenue by Countries
6.1 Europe Fragile X Syndrome Revenue by Countries (2015-2020)
6.2 Germany Fragile X Syndrome Revenue and Growth Rate (2015-2020)
6.3 UK Fragile X Syndrome Revenue and Growth Rate (2015-2020)
6.4 France Fragile X Syndrome Revenue and Growth Rate (2015-2020)
6.5 Russia Fragile X Syndrome Revenue and Growth Rate (2015-2020)
6.6 Italy Fragile X Syndrome Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Fragile X Syndrome Revenue by Countries
7.1 Asia-Pacific Fragile X Syndrome Revenue by Countries (2015-2020)
7.2 China Fragile X Syndrome Revenue and Growth Rate (2015-2020)
7.3 Japan Fragile X Syndrome Revenue and Growth Rate (2015-2020)
7.4 Korea Fragile X Syndrome Revenue and Growth Rate (2015-2020)
7.5 India Fragile X Syndrome Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Fragile X Syndrome Revenue and Growth Rate (2015-2020)
8 South America Fragile X Syndrome Revenue by Countries
8.1 South America Fragile X Syndrome Revenue by Countries (2015-2020)
8.2 Brazil Fragile X Syndrome Revenue and Growth Rate (2015-2020)
8.3 Argentina Fragile X Syndrome Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Fragile X Syndrome by Countries
9.1 Middle East & Africa Fragile X Syndrome Revenue by Countries (2015-2020)
9.2 Saudi Arabia Fragile X Syndrome Revenue and Growth Rate (2015-2020)
9.3 UAE Fragile X Syndrome Revenue and Growth Rate (2015-2020)
9.4 Egypt Fragile X Syndrome Revenue and Growth Rate (2015-2020)
9.5 South Africa Fragile X Syndrome Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Fragile X Syndrome Revenue and Market Share by Type (2015-2020)
10.2 Global Fragile X Syndrome Market Forecast by Type (2019-2024)
10.3 ACT-01 Revenue Growth Rate (2015-2025)
10.4 AMO-01 Revenue Growth Rate (2015-2025)
10.5 ANAVEX-273 Revenue Growth Rate (2015-2025)
10.6 AUT-00206 Revenue Growth Rate (2015-2025)
10.7 Bryostatin-1 Revenue Growth Rate (2015-2025)
10.8 Cannabidiol Revenue Growth Rate (2015-2025)
10.9 Others Revenue Growth Rate (2015-2025)
11 Global Fragile X Syndrome Market Segment by Application
11.1 Global Fragile X Syndrome Revenue Market Share by Application (2015-2020)
11.2 Fragile X Syndrome Market Forecast by Application (2019-2024)
11.3 Clinic Revenue Growth (2015-2020)
11.4 Hopital Revenue Growth (2015-2020)
11.5 Research Center Revenue Growth (2015-2020)
12 Global Fragile X Syndrome Market Size Forecast (2021-2025)
12.1 Global Fragile X Syndrome Market Size Forecast (2021-2025)
12.2 Global Fragile X Syndrome Market Forecast by Regions (2021-2025)
12.3 North America Fragile X Syndrome Revenue Market Forecast (2021-2025)
12.4 Europe Fragile X Syndrome Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Fragile X Syndrome Revenue Market Forecast (2021-2025)
12.6 South America Fragile X Syndrome Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Fragile X Syndrome Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Fragile X Syndrome Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Fragile X Syndrome by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Fragile X Syndrome Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Fragile X Syndrome Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Aelis Farma SAS Corporate Information, Location and Competitors
Table 6. Aelis Farma SAS Fragile X Syndrome Major Business
Table 7. Aelis Farma SAS Fragile X Syndrome Total Revenue (USD Million) (2017-2018)
Table 8. Aelis Farma SAS SWOT Analysis
Table 9. Aelis Farma SAS Fragile X Syndrome Product and Solutions
Table 10. Aelis Farma SAS Fragile X Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. MI.TO. Technology S.r.L. Corporate Information, Location and Competitors
Table 12. MI.TO. Technology S.r.L. Fragile X Syndrome Major Business
Table 13. MI.TO. Technology S.r.L. Fragile X Syndrome Total Revenue (USD Million) (2018-2019)
Table 14. MI.TO. Technology S.r.L. SWOT Analysis
Table 15. MI.TO. Technology S.r.L. Fragile X Syndrome Product and Solutions
Table 16. MI.TO. Technology S.r.L. Fragile X Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Confluence Pharmaceuticals LLC Corporate Information, Location and Competitors
Table 18. Confluence Pharmaceuticals LLC Fragile X Syndrome Major Business
Table 19. Confluence Pharmaceuticals LLC Fragile X Syndrome Total Revenue (USD Million) (2017-2018)
Table 20. Confluence Pharmaceuticals LLC SWOT Analysis
Table 21. Confluence Pharmaceuticals LLC Fragile X Syndrome Product and Solutions
Table 22. Confluence Pharmaceuticals LLC Fragile X Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Alcobra Ltd Corporate Information, Location and Competitors
Table 24. Alcobra Ltd Fragile X Syndrome Major Business
Table 25. Alcobra Ltd Fragile X Syndrome Total Revenue (USD Million) (2017-2018)
Table 26. Alcobra Ltd SWOT Analysis
Table 27. Alcobra Ltd Fragile X Syndrome Product and Solutions
Table 28. Alcobra Ltd Fragile X Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Marinus Pharmaceuticals, Inc. Corporate Information, Location and Competitors
Table 30. Marinus Pharmaceuticals, Inc. Fragile X Syndrome Major Business
Table 31. Marinus Pharmaceuticals, Inc. Fragile X Syndrome Total Revenue (USD Million) (2017-2018)
Table 32. Marinus Pharmaceuticals, Inc. SWOT Analysis
Table 33. Marinus Pharmaceuticals, Inc. Fragile X Syndrome Product and Solutions
Table 34. Marinus Pharmaceuticals, Inc. Fragile X Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. AMO Pharma Limited Corporate Information, Location and Competitors
Table 36. AMO Pharma Limited Fragile X Syndrome Major Business
Table 37. AMO Pharma Limited Fragile X Syndrome Total Revenue (USD Million) (2017-2018)
Table 38. AMO Pharma Limited SWOT Analysis
Table 39. AMO Pharma Limited Fragile X Syndrome Product and Solutions
Table 40. AMO Pharma Limited Fragile X Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Ovid Therapeutics Inc. Corporate Information, Location and Competitors
Table 42. Ovid Therapeutics Inc. Fragile X Syndrome Major Business
Table 43. Ovid Therapeutics Inc. Fragile X Syndrome Total Revenue (USD Million) (2017-2018)
Table 44. Ovid Therapeutics Inc. SWOT Analysis
Table 45. Ovid Therapeutics Inc. Fragile X Syndrome Product and Solutions
Table 46. Ovid Therapeutics Inc. Fragile X Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. F. Hoffmann-La Roche Ltd. Corporate Information, Location and Competitors
Table 48. F. Hoffmann-La Roche Ltd. Fragile X Syndrome Major Business
Table 49. F. Hoffmann-La Roche Ltd. Fragile X Syndrome Total Revenue (USD Million) (2017-2018)
Table 50. F. Hoffmann-La Roche Ltd. SWOT Analysis
Table 51. F. Hoffmann-La Roche Ltd. Fragile X Syndrome Product and Solutions
Table 52. F. Hoffmann-La Roche Ltd. Fragile X Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Eli Lilly and Company Corporate Information, Location and Competitors
Table 54. Eli Lilly and Company Fragile X Syndrome Major Business
Table 55. Eli Lilly and Company Fragile X Syndrome Total Revenue (USD Million) (2017-2018)
Table 56. Eli Lilly and Company SWOT Analysis
Table 57. Eli Lilly and Company Fragile X Syndrome Product and Solutions
Table 58. Eli Lilly and Company Fragile X Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Neuren Pharmaceuticals Limited Corporate Information, Location and Competitors
Table 60. Neuren Pharmaceuticals Limited Fragile X Syndrome Major Business
Table 61. Neuren Pharmaceuticals Limited Fragile X Syndrome Total Revenue (USD Million) (2017-2018)
Table 62. Neuren Pharmaceuticals Limited SWOT Analysis
Table 63. Neuren Pharmaceuticals Limited Fragile X Syndrome Product and Solutions
Table 64. Neuren Pharmaceuticals Limited Fragile X Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Sage Therapeutics, Inc. Corporate Information, Location and Competitors
Table 66. Sage Therapeutics, Inc. Fragile X Syndrome Major Business
Table 67. Sage Therapeutics, Inc. Fragile X Syndrome Total Revenue (USD Million) (2017-2018)
Table 68. Sage Therapeutics, Inc. SWOT Analysis
Table 69. Sage Therapeutics, Inc. Fragile X Syndrome Product and Solutions
Table 70. Sage Therapeutics, Inc. Fragile X Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Zynerba Pharmaceuticals, Inc. Corporate Information, Location and Competitors
Table 72. Zynerba Pharmaceuticals, Inc. Fragile X Syndrome Major Business
Table 73. Zynerba Pharmaceuticals, Inc. Fragile X Syndrome Total Revenue (USD Million) (2017-2018)
Table 74. Zynerba Pharmaceuticals, Inc. SWOT Analysis
Table 75. Zynerba Pharmaceuticals, Inc. Fragile X Syndrome Product and Solutions
Table 76. Zynerba Pharmaceuticals, Inc. Fragile X Syndrome Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Global Fragile X Syndrome Revenue (Million USD) by Players (2015-2020)
Table 78. Global Fragile X Syndrome Revenue Share by Players (2015-2020)
Table 79. Global Fragile X Syndrome Revenue (Million USD) by Regions (2015-2020)
Table 80. Global Fragile X Syndrome Revenue Market Share by Regions (2015-2020)
Table 81. North America Fragile X Syndrome Revenue by Countries (2015-2020)
Table 82. North America Fragile X Syndrome Revenue Market Share by Countries (2015-2020)
Table 83. Europe Fragile X Syndrome Revenue (Million USD) by Countries (2015-2020)
Table 84. Asia-Pacific Fragile X Syndrome Revenue (Million USD) by Countries (2015-2020)
Table 85. South America Fragile X Syndrome Revenue by Countries (2015-2020)
Table 86. South America Fragile X Syndrome Revenue Market Share by Countries (2015-2020)
Table 87. Middle East and Africa Fragile X Syndrome Revenue (Million USD) by Countries (2015-2020)
Table 88. Middle East and Africa Fragile X Syndrome Revenue Market Share by Countries (2015-2020)
Table 89. Global Fragile X Syndrome Revenue (Million USD) by Type (2015-2020)
Table 90. Global Fragile X Syndrome Revenue Share by Type (2015-2020)
Table 91. Global Fragile X Syndrome Revenue Forecast by Type (2021-2025)
Table 92. Global Fragile X Syndrome Revenue by Application (2015-2020)
Table 93. Global Fragile X Syndrome Revenue Share by Application (2015-2020)
Table 94. Global Fragile X Syndrome Revenue Forecast by Application (2021-2025)
Table 95. Global Fragile X Syndrome Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Fragile X Syndrome Picture
Figure 2. Global Fragile X Syndrome Revenue Market Share by Type in 2019
Figure 3. ACT-01 Picture
Figure 4. AMO-01 Picture
Figure 5. ANAVEX-273 Picture
Figure 6. AUT-00206 Picture
Figure 7. Bryostatin-1 Picture
Figure 8. Cannabidiol Picture
Figure 9. Others Picture
Figure 10. Fragile X Syndrome Revenue Market Share by Application in 2019
Figure 11. Clinic Picture
Figure 12. Hopital Picture
Figure 13. Research Center Picture
Figure 14. Global Fragile X Syndrome Revenue (USD Million) and Growth Rate (2015-2025)
Figure 15. North America Fragile X Syndrome Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Europe Fragile X Syndrome Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Asia-Pacific Fragile X Syndrome Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. South America Fragile X Syndrome Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Middle East and Africa Fragile X Syndrome Revenue (Million USD) and Growth Rate (2015-2025)
Figure 20. Global Fragile X Syndrome Revenue (Million USD) and Growth Rate (2015-2025)
Figure 21. Global Fragile X Syndrome Revenue Share by Players in 2019
Figure 22. Global Top 5 Players Fragile X Syndrome Revenue Market Share in 2019
Figure 23. Global Top 10 Players Fragile X Syndrome Revenue Market Share in 2019
Figure 24. Key Players Market Share Trend
Figure 25. Global Fragile X Syndrome Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 26. Global Fragile X Syndrome Revenue Market Share by Regions (2015-2020)
Figure 27. Global Fragile X Syndrome Revenue Market Share by Regions in 2018
Figure 28. North America Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 29. Europe Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 30. Asia-Pacific Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 31. South America Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 32. Middle East and Africa Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 33. North America Fragile X Syndrome Revenue Market Share by Countries (2015-2020)
Figure 34. North America Fragile X Syndrome Revenue Market Share by Countries in 2019
Figure 35. USA Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 36. Canada Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 37. Mexico Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 38. Europe Fragile X Syndrome Revenue Market Share by Countries (2015-2020)
Figure 39. Europe Fragile X Syndrome Revenue Market Share by Countries in 2019
Figure 40. Germany Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 41. UK Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 42. France Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 43. Russia Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 44. Italy Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 45. Asia-Pacific Fragile X Syndrome Revenue Market Share by Countries (2015-2020)
Figure 46. Asia-Pacific Fragile X Syndrome Revenue Market Share by Countries in 2019
Figure 47. China Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 48. Japan Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 49. Korea Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 50. India Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 51. Southeast Asia Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 52. South America Fragile X Syndrome Revenue Market Share by Countries (2015-2020)
Figure 53. South America Fragile X Syndrome Revenue Market Share by Countries in 2019
Figure 54. Brazil Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 55. Argentina Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 56. Middle East and Africa Fragile X Syndrome Revenue Market Share by Countries (2015-2020)
Figure 57. Middle East and Africa Fragile X Syndrome Revenue Market Share by Countries in 2019
Figure 58. Saudi Arabia Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 59. UAE Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 60. Egypt Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 61. South Africa Fragile X Syndrome Revenue and Growth Rate (2015-2020)
Figure 62. Global Fragile X Syndrome Revenue Share by Type (2015-2020)
Figure 63. Global Fragile X Syndrome Revenue Share by Type in 2019
Figure 64. Global Fragile X Syndrome Market Share Forecast by Type (2021-2025)
Figure 65. Global ACT-01 Revenue Growth Rate (2015-2020)
Figure 66. Global AMO-01 Revenue Growth Rate (2015-2020)
Figure 67. Global ANAVEX-273 Revenue Growth Rate (2015-2020)
Figure 68. Global AUT-00206 Revenue Growth Rate (2015-2020)
Figure 69. Global Bryostatin-1 Revenue Growth Rate (2015-2020)
Figure 70. Global Cannabidiol Revenue Growth Rate (2015-2020)
Figure 71. Global Others Revenue Growth Rate (2015-2020)
Figure 72. Global Fragile X Syndrome Revenue Share by Application (2015-2020)
Figure 73. Global Fragile X Syndrome Revenue Share by Application in 2019
Figure 74. Global Fragile X Syndrome Market Share Forecast by Application (2021-2025)
Figure 75. Global Clinic Revenue Growth Rate (2015-2020)
Figure 76. Global Hopital Revenue Growth Rate (2015-2020)
Figure 77. Global Research Center Revenue Growth Rate (2015-2020)
Figure 78. Global Fragile X Syndrome Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 79. Global Fragile X Syndrome Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 80. Global Fragile X Syndrome Revenue Market Share Forecast by Regions (2021-2025)
Figure 81. North America Fragile X Syndrome Revenue Market Forecast (2021-2025)
Figure 82. Europe Fragile X Syndrome Revenue Market Forecast (2021-2025)
Figure 83. Asia-Pacific Fragile X Syndrome Revenue Market Forecast (2021-2025)
Figure 84. South America Fragile X Syndrome Revenue Market Forecast (2021-2025)
Figure 85. Middle East and Africa Fragile X Syndrome Revenue Market Forecast (2021-2025)
Figure 86. Sales Channel: Direct Channel vs Indirect Channel
脆弱X症候群の世界市場（～2026年） Market Analysis and Insights: Global Fragile X Syndrome Market The global Fragile X Syndrome market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Fragile X Syndrome Scope and Market Size Fragile X Syndrome market is segment…- レット症候群治療薬の世界市場（～2026年） Market Analysis and Insights: Global Rett Syndrome Therapeutics Market The global Rett Syndrome Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Rett Syndrome Therapeutics Scope and Market Size Rett Syndrom…
- 間欠的発熱症候群の世界市場（～2026年） Periodic fever syndrome are a set of disorders characterized by recurrent episodes of systemic and organ-specific inflammation. The syndromes are diverse, but tend to cause episodes of fever, joint pains, skin rashes, abdominal pains and may lead to chronic complications such as amyloidosis. Market …
- ドラベ症候群治療薬の世界市場（～2026年） Market Analysis and Insights: Global Dravet Syndrome Thereapeutics Market The global Dravet Syndrome Thereapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Dravet Syndrome Thereapeutics Scope and Market Size Dra…
- チャーグ・ストラウス症候群の世界市場（～2026年） Churg Strauss syndrome is a disorder that causes inflammation in blood vessels. This restricts the blood flow to vital organs and tissues. Sometimes it leads to permanent damage of tissues. This condition is also known as eosinophilic granulomatosis with polyangiitis. Asthma is the most common sign …